Division of Intensive Care Medicine, Department of Anaesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Department of Cardiovascular Research, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.
Shock. 2018 Oct;50(4):395-400. doi: 10.1097/SHK.0000000000001087.
Patients resuscitated from cardiac arrest commonly develop an inflammatory response called post-cardiac arrest syndrome that clinically resembles septic shock.Procalcitonin and presepsin are associated with inflammation. We hypothesized that these biomarkers reflect the severity of post-cardiac arrest syndrome and predict short-term hemodynamical instability and long-term neurological outcome after cardiac arrest.
As a subcohort analysis of a prospective, observational, multicenter study "FINNRESUSCI," we obtained plasma from 277 intensive care unit (ICU) patients treated following out-of-hospital cardiac arrest (OHCA). Procalcitonin and presepsin levels were measured 0 to 6 h from ICU admission and 24, 48, and 96 h thereafter. We defined poor outcome as a 12-month Cerebral Performance Category of 3 to 5. We tested statistical associations between biomarkers and hemodynamical parameters and outcome with regression models.
Plasma procalcitonin had best predictive value for 12-month poor outcome at 96 h (AUC 0.76; 95% CI 0.68-0.83) and presepsin at ICU admission (AUC 0.72; 95% CI 0.65-0.78). Elevated procalcitonin concentration at ICU admission predicted unstable hemodynamics in the following 48 h in a linear regression model. In a multivariate logistic regression model with clinical variables, only procalcitonin at 96 h had independent prognostic value for poor 12-month neurological outcome.
Elevated procalcitonin is associated with hemodynamical instability and worsened long-term outcome in OHCA patients. The association is not strong enough for it to be used as a single predictor. Presepsin did not provide clinically relevant information for risk stratification after OHCA.
从心脏骤停中复苏的患者通常会发生称为心脏骤停后综合征的炎症反应,其在临床上类似于感染性休克。降钙素原和前降钙素原与炎症有关。我们假设这些生物标志物反映了心脏骤停后综合征的严重程度,并预测心脏骤停后的短期血流动力学不稳定和长期神经预后。
作为一项前瞻性、观察性、多中心研究“FINNRESUSCI”的亚组分析,我们从接受院外心脏骤停(OHCA)治疗的 277 名重症监护病房(ICU)患者中获得了血浆。在 ICU 入院后 0 至 6 小时以及此后 24、48 和 96 小时测量降钙素原和前降钙素原水平。我们将不良预后定义为 12 个月时的脑功能状态分类为 3 至 5 分。我们使用回归模型测试了生物标志物与血流动力学参数和结局之间的统计学关联。
在 96 小时时,血浆降钙素原对 12 个月的不良预后具有最佳预测价值(AUC 0.76;95%CI 0.68-0.83),而前降钙素原在 ICU 入院时具有最佳预测价值(AUC 0.72;95%CI 0.65-0.78)。在一个线性回归模型中,ICU 入院时升高的降钙素原浓度预测了接下来 48 小时的不稳定血流动力学。在一个包含临床变量的多变量逻辑回归模型中,只有在 96 小时时的降钙素原具有 12 个月不良神经预后的独立预后价值。
在 OHCA 患者中,升高的降钙素原与血流动力学不稳定和长期预后恶化有关。这种关联还不够强,无法作为单一预测因素。在 OHCA 后,前降钙素原未提供用于风险分层的临床相关信息。